PRASCO
GenericsPRASCO is a generic drug manufacturer focused on Respiratory, Dermatology, Oncology.
PRASCO's Key Drugs
PRASCO's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PRASCO's Recent FDA Approvals
New NDA/BLA approvals for PRASCO over the last two years — novel drugs only, excluding generics and label supplements.
PRASCO's Therapeutic Areas
PRASCO's approved drugs and pipeline span 3 therapeutic areas, led by Respiratory and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PRASCO's Top Competitors
PRASCO's closest competitors by therapeutic-area and drug-target overlap include Bayer, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PRASCO Pipeline Snapshot
Active clinical trials for PRASCO across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1971-10-20
- Latest
- 2025-05-19
- Applications
- 6